Determining cut-points for Alzheimer’s disease biomarkers: statistical issues, methods and challenges

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Evidence for Ordering of Alzheimer Disease Biomarkers

(2011) Clifford R. Jack   ARCHIVES OF NEUROLOGY

Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42

(2010) Jonathan M. Schott et al.   ANNALS OF NEUROLOGY

Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People

(2010) Geert De Meyer   ARCHIVES OF NEUROLOGY

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

Bias in Sensitivity and Specificity Caused by Data-Driven Selection of Optimal Cutoff Values: Mechanisms, Magnitude, and Solutions

(2008) M. M.G. Leeflang et al.   CLINICAL CHEMISTRY